ADHD community seeks DEA action in med shortages

"When you have a controlled substance problem, the DEA has to be involved in fixing it," says Ruth Hughes, CEO at Children and Adults with Attention Deficit/Hyperactivity Disorder. Drugs like Adderall and Ritalin, which have controlled-substance APIs among the 400 basic substances and derivatives regulated by the U.S. Drug Enforcement Agency, present an additional hurdle when it comes to resolving shortages. "It is not sufficient to say it is an industry problem. We need to figure out how to build more flexibility into the system." Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.